Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegcetacoplan - Apellis Pharmaceuticals/Swedish Orphan Biovitrum

Drug Profile

Pegcetacoplan - Apellis Pharmaceuticals/Swedish Orphan Biovitrum

Alternative Names: APL-2; Aspaveli; EMPAVELI; Pegcetacoplan injection - Apellis Pharmaceuticals/Swedish Orphan Biovitrum; SYFOVRE

Latest Information Update: 13 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Apellis Pharmaceuticals
  • Developer Apellis Pharmaceuticals; Swedish Orphan Biovitrum
  • Class Anti-inflammatories; Anti-ischaemics; Antianaemics; Antithrombotics; Cyclic peptides; Eye disorder therapies; Polyethylene glycols; Urologics
  • Mechanism of Action Complement C3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Autoimmune haemolytic anaemia; Paroxysmal nocturnal haemoglobinuria; Glomerulonephritis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Age-related macular degeneration; Paroxysmal nocturnal haemoglobinuria
  • Phase III Membranoproliferative glomerulonephritis
  • Phase II Glomerulonephritis; IgA nephropathy; Lupus nephritis; Membranous glomerulonephritis; Thrombotic microangiopathy
  • Phase I/II Wet age-related macular degeneration
  • Discontinued Amyotrophic lateral sclerosis; Autoimmune haemolytic anaemia; Ischaemia

Most Recent Events

  • 10 Jun 2024 Updated fficacy data from phase III GALE extension trial in Age-related macular degeneration released by Apellis Pharmaceuticals
  • 24 May 2024 Efficacy and adverse event data from the phase II NOBLE trial in Membranoproliferative glomerulonephritis released by Apellis Pharmaceuticals
  • 08 May 2024 Registered for Paroxysmal nocturnal haemoglobinuria (Treatment-naive) in European Union (SC)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top